Abdominal chemotherapy after surgery may improve mesothelioma outcomes
NCT ID NCT06057935
First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether giving chemotherapy directly into the abdomen (intraperitoneal) or into a vein (intravenous) after surgery and heated chemotherapy works better for people with malignant peritoneal mesothelioma. Participants must have had successful removal of visible cancer. The study compares how long the cancer stays under control with each approach.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pemetrexed and cisplatin (or carboplatin) given either into the abdomen or into a vein
- What this could lead to
- If it works, this could show that giving chemotherapy directly into the abdomen after surgery improves how long the cancer stays under control.
- What could go wrong
- This is a mid-stage trial with only 64 participants, so results may not apply to everyone. Chemotherapy has side effects, and the intraperitoneal route may cause more abdominal discomfort or infection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT MESOTHELIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Allegheny Health Network (Data Collection Only)
RECRUITINGPittsburgh, Pennsylvania, 15212, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
RECRUITINGBasking Ridge, New Jersey, 07920, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
RECRUITINGMontvale, New Jersey, 07645, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Commack (Limited Protocol Activities)
RECRUITINGCommack, New York, 11725, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
RECRUITINGMiddletown, New Jersey, 07748, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
RECRUITINGUniondale, New York, 11553, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Westchester (Limited Protocol Activites)
RECRUITINGHarrison, New York, 10604, United States
Contact Phone: •••-•••-••••
-
Rutgers University (Data Collection Only)
NOT_YET_RECRUITINGNew Brunswick, New Jersey, 08903, United States
Contact Phone: •••-•••-••••
-
University of Chicago (Data Collection Only)
RECRUITINGChicago, Illinois, 60637, United States
Contact Phone: •••-•••-••••
-
University of Michigan (Data Collection Only)
NOT_YET_RECRUITINGAnn Arbor, Michigan, 48109, United States
Contact Phone: •••-•••-••••
-
University of Nebraska (Data collection only)
NOT_YET_RECRUITINGOmaha, Nebraska, 68198-7680, United States
Contact Phone: •••-•••-••••
-
Washington University (Data Collection Only)
NOT_YET_RECRUITINGSt Louis, Missouri, 63110, United States
Contact Phone: •••-•••-••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chest-Injected drug drain Cancer's fluid trap?
- New imaging tracer could spot hidden cancers and fibrosis in one scan
- Experimental pill SHY-ONC6 takes on Hard-to-Treat cancers
- Engineered immune cells take aim at Mesothelin-Positive tumors
- Experimental drug tazemetostat offered to patients with rare, aggressive tumors
- New pill aims to shrink Hard-to-Treat cancers